Geburtshilfe Frauenheilkd 2020; 80(10): e193
DOI: 10.1055/s-0040-1718146
Poster
Mittwoch, 7.10.2020
Gynäkologische Onkologie II

Retrospective unicenter analysis of uterine sarcoma treatment and survival

A Huß
1   Albert-Ludwigs-Universität Freiburg, Frauenklinik, Freiburg im Breisgau, Deutschland
,
B Hoang
1   Albert-Ludwigs-Universität Freiburg, Frauenklinik, Freiburg im Breisgau, Deutschland
,
M Klar
1   Albert-Ludwigs-Universität Freiburg, Frauenklinik, Freiburg im Breisgau, Deutschland
,
I Juhasz-Böss
1   Albert-Ludwigs-Universität Freiburg, Frauenklinik, Freiburg im Breisgau, Deutschland
,
M Bossart
1   Albert-Ludwigs-Universität Freiburg, Frauenklinik, Freiburg im Breisgau, Deutschland
› Author Affiliations
 

Objective The aim of this study was to assess treatment modalities, prognostic factors and survival in leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) patients at the Department of Obstetrics and Gynecology at Freiburg University (UFK), Germany.

Material and methods This unicenter, retrospective cohort study included ESS and LMS patients treated at UFK between January 2000 and December 2016. Descriptive analyses were conducted, including univariate analyses. Progression-free survival (PFS) and overall survival (OS) was calculated and visualized in Kaplan-Meier curves.

Results 63 patients, 46 LMS and 17 ESS patients, with a median age of 51.0 years at time of diagnosis (range 18-83) were incorporated. R0-resection (Hazard ratio (HR) 0.32, 95 %-confidence interval (CI): 0.114-0.903, p=0.031) and over 20 mitoses/10 high power fields (HR 4.01, 95 %-CI: 1.13-14.2, p=0.031) were significant prognostic factors for PFS in LMS. Good tumor differentiation was prognostic for OS in ESS (HR 0.07, 95 %-CI: 0.01-0.97 p=0.047). Other prognostic factors did not show statistical significance.

PFS for the total cohort was 14.0 months (95 %-CI: 9.72-18.28) and OS was 36.0 months (22.05-49.95). The LMS subgroup showed longer PFS (15 months (4.7-25.3)) and OS (42.0 months (31.4-52.6)) than the ESS subgroup (PFS 13.0 months (0.8-25.2) and OS 32.0 months (0.8-90.4)).

Conclusion During a long observation period of 16 years, 63 patients could be included and treatment modalities varied, which limits identification of prognostic factors. For these rare uterine entities, multicenter collaboration and data collection as in the “REGSA”, a German prospective register-study, is warranted to standardize and optimize treatment.

Zoom Image
Abb.1 Bitte Abbildungslegende ergänzen.


Publication History

Article published online:
07 October 2020

© 2020. Thieme. All rights reserved.
Rüdigerstraße 14, 70469 Stuttgart, Germany